Aveta Biomics to Present at the Upcoming 2025 ESMO Congress
BEDFORD, MA, UNITED STATES, October 13, 2025 /EINPresswire.com/ — Aveta Biomics, a clinicalstage biotechnology company developing first-in-class drugs that reprogram the immune system to fight cancer, today announced the poster presentation of new clinical and translational findings from its Phase IIa study of APG-157 at the European Society for Medical Oncology (ESMO) Congress, taking place […]
Aveta Biomics to Present at the Upcoming 2025 ESMO Congress Read More »
